dr. M.G. (Matthijs) Bossong Assistant Professor
Matthijs Bossong studied Biomedical Sciences at Utrecht University. After completing his PhD in Utrecht on the role of the endocannabinoid system in human brain functions relevant for psychiatric disorders, he started his first postdoc position in September 2011 at the Institute of Psychiatry of King’s College London. Here, supported by an NWO Rubicon fellowship, Matthijs worked on two multimodal neuroimaging studies with people at an ultra-high risk for developing psychosis. One of these projects involved a treatment with the cannabinoid compound cannabidiol. In September 2014, he started his second postdoc at the Department of Psychiatry of the UMC Utrecht, where he coordinated a large-scale international multicenter study in which the potential of omega-3 fatty acids in the prevention of psychosis was examined in adolescent at-risk individuals. Supported by both an NWO Veni fellowship and a Rudolf Magnus Young Talent Fellowship, Matthijs is currently working as Assistant Professor on a pharmacological neuroimaging study investigating the impact of cannabidiol treatment on brain function of patients with a psychotic disorder.
Bossong M.G., Antoniades M., Azis M., Samson C., Quinn B., Bonoldi I., Modinos G., Pérez J., Howes O.D., Stone J., Allen P., McGuire P. (2019) Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry 76, 199-207.
Bhattacharyya S., Wilson R., Appiah-Kusi E., O'Neill A., Brammer M., Perez J., Murray R., Allen P., Bossong M.G., McGuire P. (2018) Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial. JAMA Psychiatry 75, 1107-17.
Iseger T.A., Bossong M.G. (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research 162 (1-3), 153 - 161.
Bossong M.G., Jansma J.M., Van Hell H.H., Jager G., Oudman E., Saliasi E., Kahn R.S., Ramsey N.F. (2012) Effects of Δ9-tetrahydrocannabinol on human working memory function. Biological Psychiatry 71 (8), 693 - 699.
Bossong M.G., Niesink R.J. (2010) Adolescent brain maturation, the endogenous cannabinoid system and cannabis-induced schizophrenia. Progress in Neurobiology 92 (3), 370 - 385.
Bossong M.G., Van Berckel B.N.M., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., Van Gerven J.M.A., Ramsey N.F., Lammertsma A.A., Kahn R.S. (2009) ∆9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34 (3), 759 - 766.
Van Berckel B.N.M., Bossong M.G., Van Haaren N., Boellaard R., Comans E.F.I., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. (2008) Microglia activation in recent onset schizophrenia: a quantitative (R)-[11C]PK11195 PET study. Biological Psychiatry 64 (9), 820 - 822
Fellowship and Awards
Bossong M.G. Examining synaptic density in the living brain of schizophrenia patients. Rudolf Magnus Young Talent Fellowship, 01/10/2017 - 01/01/2020, €200,000
Bossong M.G. Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia. Netherlands Organisation for Scientific Research, Fellowship (VENI grant), 01/01/2016 - 01/01/2019, €250,000
Bossong M.G. Towards prevention of schizophrenia: the potential of a cannabidiol as a novel antipsychotic agent. Netherlands Organisation for Scientific Research, Fellowship (Rubicon grant), 01/05/2012 - 01/05/2014, €144,937